Show results for
Refine by
Innate Immunity Suppliers Serving Latvia
35 companies found
based inExeter, UNITED KINGDOM
Attomarker is a British company focused on nanophotonic biochemical testing. It was founded in 2008, and spun out from Professor Andrew Shaw’s research group at the University of Exeter. It has won numerous prestigious awards for innovation and been ...
Attomarker has developed a technology platform that will measure the concentration of biomarkers in blood samples, but it can be readily extended to saliva or even cerebral spinal fluid. The blood contains many components – biomarkers – ...
based inParis, FRANCE
Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis. Enterome is using this ...
Sibofimloc is a first-in-class, orally administered small molecule that is specifically designed to reduce the inflammatory cascade underlying Crohn’s disease and remain gut-restricted, to minimize absorption into the bloodstream. ...
based inNew York, NEW YORK (USA)
Creative Peptides is specialized in the process development and the manufacturing of bioactive peptides. We are dedicated to offering custom peptide synthesis, process development, GMP manufacturing as well as catalog products for customers in ...
On the basis of extensive experience in peptide synthesis, Creative Peptides proudly offers the most comprehensive glycopeptides synthesis services to our worldwide clients. Our scientists are committed to deliver high quality glycopeptides which ...
based inAthens, GEORGIA (US) (USA)
Athens Research & Technology Inc. has been purifying human proteins and developing polyclonal antisera to those proteins since 1986. We specialize in highly pure, highly active human proteins. We routinely purify serine proteases, protease ...
IgA is the most abundant immunoglobulin in body fluids and the second most abundant immunoglobulin in plasma, found at a concentration of 0.4 to 2.2 mg/ml. It plays a very important role in the first specific defense against natural infection. ...
based inGlasgow, UNITED KINGDOM
We’re a leading microbiome therapeutics company. We have established proprietary MHRA licensed manufacturing capabilities and a supply chain model that enables us to leverage a pipeline of internal and partnered programmes around our lead asset, ...
Immuno-oncology exploits the mechanisms of the body’s own natural immune response, either by stimulating or suppressing it, to fight ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
Innovative antibody-based molecular concepts. New treatments for cancer that leverage our own immune system to attack and destroy cancer cells can provide long-term and durable therapeutic responses in patients suffering from life-threatening ...
based inTokyo, JAPAN
Healios will expand the possibilities for curing diseases to increase and further enrich quality of life through the development and supply of regenerative medicine products as part of the rapid progress of regenerative medicine taking place in the ...
Cancer is the leading cause of death in Japan, with approximately 90% of those deaths said to be caused by solid ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
DSP-0509 is an investigational Toll-like receptor (TLR) 7 agonist, which is hypothesized to induce cytokine production, activate cytotoxic T lymphocytes, and sustain immune-mediated antitumor ...
based inCambridge, MASSACHUSETTS (USA)
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP ...
based inNewark, DELAWARE (USA)
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across ...
IL-15,Interleukin-15,IL15,Interleukin ...
based inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
Myeloid is focused on advancing its ATAK CAR monocytes, which are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. Additionally, Myeloid has streamlined manufacturing for its ...
based inSeattle, WASHINGTON (USA)
Nexelis is your partner for assay and biomarker development, advanced bioanalytical and laboratory testing, and translational immunology. As the leading specialty laboratory, we have unrivaled expertise in immunology, specifically in the areas of ...
Custom Assay Development to Advance Molecules. You need reliable approaches to support what’s next in your development programs whether they are complex small molecules, advanced biologics, or vaccines. At Nexelis, a Q² Solutions Company, ...
based inSan Francisco, CALIFORNIA (USA)
We were founded with the mission of creating a world without infectious disease. We are a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. ...
Moving beyond more traditional approaches that are used to evoke adaptive immunity or that directly target pathogens, where the development of resistance can occur, we plan to target host proteins as a means of creating ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
We are developing CYNK-101 as a combination treatment for multiple cancer indications. CYNK-101 is manufactured from a specific type of immune cell, NK cells, that we extract from postpartum placentas and then genetically engineer to increase cell ...
based inYongin-si, SOUTH KOREA
Txinno Bioscience is developing anti-cancer treatments focused on two intertwined aspects of physiology of tumor tissue. Tcino Bioscience Co., Ltd. has secured and built core platform technologies such as small molecule innovative anticancer drug ...
By hydrolyzing cGAMP (natural ligand of STING) into AMP and GMP, ENPP1 negatively regulates STING-mediated type I interferon production and subsequently prevents innate immune response against tumor. It was ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
Our clinically validated T-SIGn® viral vector platform delivers multiple transgene payloads that re-program the tumor microenvironment of both primary and metastatic tumors. Our platform can integrate rationally designed synthetic agents to ...
based inLausanne, SWITZERLAND
AB2 Bio Ltd., located at the Innovation Park of the École Polytechnique Fédérale de Lausanne (EPFL), is a drug discovery and development company focused on developing “best in class” innovative therapies for the treatment of inflammatory diseases ...
People with HLH usually develop symptoms within the first months or years of life. Symptoms may include fever, enlarged liver or spleen, cytopenia (decreased number of blood cells), and neurological abnormalities. All forms of HLH, including cases ...
based inBrighton, UNITED KINGDOM
Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention. We have two exciting late-stage clinical assets and a range of earlier research programmes. Our ...
Destiny Pharma is working in collaboration with SporeGen Limited, a UK biotechnology company working exclusively on Bacillus and its applications, to co-develop SporeGen’s SPOR-COV™ product as a novel, preventive treatment for COVID-19. ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Vγ9Vδ2 T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the ...
based inHercules, CALIFORNIA (USA)
Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products ...
The dengue virus (DENV), first isolated in 1943, is assigned to the family Flaviviridae, genus Flavivirus. It has four serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) and transmission to humans occurs via the Aedes mosquito, mainly Aedes aegypti. Its ...